[
  {
    "ts": null,
    "headline": "Biotech Stock Roundup: Patient Death Hits SRPT, INCY Study Data & More",
    "summary": "SRPT and INCY are in the spotlight this week following a report of an adverse event and study data, respectively.",
    "url": "https://finnhub.io/api/news?id=5d1c82e587e8f00e3a9ff987adb0c2aec93cc4b6ca059086ad85c1f96926b896",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1742489100,
      "headline": "Biotech Stock Roundup: Patient Death Hits SRPT, INCY Study Data & More",
      "id": 133327547,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "INCY",
      "source": "Yahoo",
      "summary": "SRPT and INCY are in the spotlight this week following a report of an adverse event and study data, respectively.",
      "url": "https://finnhub.io/api/news?id=5d1c82e587e8f00e3a9ff987adb0c2aec93cc4b6ca059086ad85c1f96926b896"
    }
  },
  {
    "ts": null,
    "headline": "3 Promising Biotechs Trading Substantially Under Consensus Analyst Firm Price Targets",
    "summary": "Discover three undervalued biotech stocks with strong assets, solid cash reserves, and major catalysts ahead. Click for the picks and why I like them.",
    "url": "https://finnhub.io/api/news?id=18230ff58e9aced29e03768ed7243a564c5bfe4a848f02601a418129b3decaba",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1742475790,
      "headline": "3 Promising Biotechs Trading Substantially Under Consensus Analyst Firm Price Targets",
      "id": 133287278,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/155151969/image_155151969.jpg?io=getty-c-w1536",
      "related": "INCY",
      "source": "SeekingAlpha",
      "summary": "Discover three undervalued biotech stocks with strong assets, solid cash reserves, and major catalysts ahead. Click for the picks and why I like them.",
      "url": "https://finnhub.io/api/news?id=18230ff58e9aced29e03768ed7243a564c5bfe4a848f02601a418129b3decaba"
    }
  },
  {
    "ts": null,
    "headline": "Natera (NASDAQ:NTRA) Q4 Earnings: Leading The Immuno-Oncology Pack",
    "summary": "Wrapping up Q4 earnings, we look at the numbers and key takeaways for the immuno-oncology stocks, including Natera (NASDAQ:NTRA) and its peers.",
    "url": "https://finnhub.io/api/news?id=e85bac298831e78bf22d36204f1aee651ea7c16900fc03b351b6aff432769054",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1742461785,
      "headline": "Natera (NASDAQ:NTRA) Q4 Earnings: Leading The Immuno-Oncology Pack",
      "id": 133325925,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "INCY",
      "source": "Yahoo",
      "summary": "Wrapping up Q4 earnings, we look at the numbers and key takeaways for the immuno-oncology stocks, including Natera (NASDAQ:NTRA) and its peers.",
      "url": "https://finnhub.io/api/news?id=e85bac298831e78bf22d36204f1aee651ea7c16900fc03b351b6aff432769054"
    }
  }
]